# A Study to Investigate Relative Bioavailability, Safety and Tolerability of Single- and Multiple-doses of Elinzanetant in Healthy Female Participants

> **NCT07229404** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 18 (actual)

## Conditions studied

- Vasomotor Symptoms

## Interventions

- **DRUG:** Treatment A
- **DRUG:** Treatment B
- **DRUG:** Treatment C

## Key facts

- **NCT ID:** NCT07229404
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-11-05
- **Primary completion:** 2026-01-14
- **Final completion:** 2026-01-14
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07229404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07229404, "A Study to Investigate Relative Bioavailability, Safety and Tolerability of Single- and Multiple-doses of Elinzanetant in Healthy Female Participants". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT07229404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*